November 2, 2020 -- Samsung Biologics has announced that its contract development and manufacturing organization (CDMO) services have been selected by two companies for their antibody candidates.
Samsung Biologics and Checkpoint Therapeutics have expanded their long-term manufacturing partnership for Checkpoint's anti-programmed cell death ligand 1 (PD-L1) antibody, cosibelimab. The agreement builds on an existing agreement in 2017. Now, Samsung Biologics will provide additional commercial-scale drug substance manufacturing for Checkpoint. Samsung will begin manufacturing in 2021.
Cosibelimab is currently under clinical investigation for the treatment of metastatic cutaneous squamous cell carcinoma. Checkpoint anticipates reporting results from the trial in mid-2021.
Samsung Biologics has also entered into a new strategic partnership with GeneQuantum Healthcare in China for the joint development of an antibody drug conjugate (ADC) for the treatment of non-small cell lung carcinoma, triple-negative breast cancer, and other solid tumors. GeneQuantum has chosen Samsung Biologics as its CDMO partner for its second antibody candidate.